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Purpose: Nerve growth factor (NGF) is a key mediator of pain signaling.
Tanezumab (TNZ) is a humanized monoclonal antibody with high
selectivity and speciﬁcity for NGF. TNZ signiﬁcantly reduces pain and
improves physical function and patient’s global assessment in patients
with chronic pain. From June 2010 to August 2012 the US Food and Drug
Administration imposed a partial clinical hold on noncancer pain-
related TNZ studies due to unexpected adverse events initially reported
as osteonecrosis that required total joint replacement. A prospective
analysis was conducted to evaluate the efﬁcacy and safety of TNZ with
severe symptomatic osteoarthritis (OA).
Methods: Four, phase 3 placebo (PBO)-controlled clinical trials of TNZ in
patients with moderate-to-severe OA of the knee or hip which com-
pleted before the clinical hold were pooled for evaluating efﬁcacy in
patients with severe OA (deﬁned as those with baseline Western
Ontario andMcMasters Universities Osteoarthritis [WOMAC] pain score
7 [on 11-point numeric rating scale], WOMAC physical function score
of 7, and score of “poor” or “very poor” in the Patient’s Global
Assessment [PGA] of OA). Nine phase 3 controlled OA studies were
pooled to evaluate safety. Patients received 1 to 3 injections of intra-
venous TNZ 2.5, 5, or 10 mg every 8 weeks, naproxen 500 mg twice
daily, or PBO. Efﬁcacy was assessed as 3 co-primary endpoints: WOMAC
pain, WOMAC physical function, and PGA of OA; percentages of patients
with 30%, 50%, 70%, and 90% improvement on the WOMAC Pain
subscale were secondary endpoints. Safety assessments included
adverse event documentation, physical and neurologic examinations,
and laboratory tests. Patients who reported abnormal peripheral sen-
sation and/or had clinically signiﬁcant neurological exam ﬁndings
underwent neurological consultation.
Results: In the overall population in the 4 studies, TNZ 2.5-10 mg
provided signiﬁcant improvement over PBO in the 3 co-primary end-
points and percentages of patients with pain reduction 30%, 50%,
70%, and 90%. Of the 2979 patient enrolled across the 4 studies, 742
(25.1%) met the criteria for severe OA. TNZ 5 and 10 mg provided sig-
niﬁcant and clinically meaningful beneﬁt versus PBO in the severe
patient subgroup across the 3 co-primary endpoints (p0.001; Figure).
Signiﬁcantly more patients treated with TNZ 5 or 10 mg reported pain
reduction 30%, 50%, 70%, and 90% than PBO-treated patients
(p0.05 for all). Incidence of adverse events, withdrawals due to
adverse events, and serious adverse events in patients treated with TNZ
was similar to patients receiving active comparator and increased over
PBO-treated patients; rates with TNZ 5 and 10 mg were similar and
elevated versus TNZ 2.5 mg. Adverse events of abnormal peripheral
sensation were more frequently reported by patients receiving TNZ
versus patients receiving PBO or active comparator. A majority of TNZ-
treated patients whose ﬁnal neurological consultations were catego-
rized as having a new or worsening peripheral neuropathy based on
clinically signiﬁcant signs or diagnostic tests were diagnosed with some
form of mononeuropathy, predominantly carpal tunnel syndrome or
radiculopathy; few patients were diagnosed with a polyneuropathy.
TNZ 10mg but not 2.5 or 5mgwas associatedwith higher rate of rapidly
progressive OA than active comparator.Conclusions: TNZ provides signiﬁcant improvement of pain, physical
function, and PGA of OA. In patients with severe OA at baseline, TNZ
provided signiﬁcant and clinically meaningful beneﬁt. Non-joint-rela-
ted safety was similar in patients treated with TNZ 2.5-10mg to patients
receiving active comparator although rates of adverse events were
increased versus PBO-treated patients. Supported by Pﬁzer Inc.
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Purpose: Selecting medications to manage severe and persistent pain
associated with osteoarthritis (OA) involves assessing comparative
beneﬁts and harms of non-steroidal anti-inﬂammatory drugs (NSAIDs)
and opioid analgesics. Few studies have compared these agents rigor-
ously. The goal of this study is to summarize the comparative effec-
tiveness of oral NSAIDs and opioids in reducing pain for persons with
knee OA.
Methods: Two reviewers independently screened reports of random-
ized controlled trials, published in English between 1982 and 2014, that
evaluated the most commonly prescribed oral NSAIDs or opioids for
knee OA.We included studies that were at least eight weeks in duration,
conducted in Western Europe, the Americas, New Zealand or Australia,
and that presented baseline and follow-up pain data using the Western
Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain
subscale, which we converted to a 0-100 scale (100 worst). The primary
outcome was the mean change in pain, adjusted to account for study
withdrawals due to lack of efﬁcacy. Using a random effects analysis to
account for heterogeneity, we calculated a ﬁnal combined estimate of
change in pain for each treatment regimen. We conducted a meta-
regression analysis to examine factors associated with greater efﬁcacy
of oral analgesia. The independent variable of primary interest was the
treatment regimen (NSAIDs vs. less potent opioids vs. potent opioids).
The meta-regression adjusted for percent of the cohort with knee OA
(vs. hip), percent of the cohort that was female, study year, and country
(exclusively US-based vs. all other).
Results: Twenty-ﬁve distinct treatment arms (14 NSAIDs [8 celecoxib, 4
diclofenac, 2 naproxen], 7 less potent opioids [6 tramadol and 1 tra-
madol/acetaminophen], and 4 potent opioids [2 hydromorphone and 2
oxycodone]) were included in the analysis. Trial duration ranged from 8
to 26 weeks; median duration was 12.5 weeks for NSAID treatment
arms and 12.0 weeks for opioid treatment arms (p[[Unsupported Char-
acter - Codename :]]¼0.015). The size of the treatment arms varied from
25 to 481 (median 235) persons for NSAID arms and from 60 to 201
(median 153) persons for opioid arms (p¼0.041). Baseline patient
demographics were similar for NSAID and opioid arms. Subjects in
groups taking NSAIDs reported lower median baseline WOMAC Pain
than subjects in groups taking opioids (56 and 61, respectively,
p¼0.041) and slightly shorter median time-since-diagnosis (6.1 years
and 7.7 years, respectively; p¼0.088). NSAID studies reported lower
median proportion of subjects withdrawing due to toxicity compared to
opioid studies (6.5% vs. 25.9%, p¼0.002) and similar median proportion
of subjects withdrawing due to insufﬁcient efﬁcacy (7.4% vs. 8.8%,
p¼0.478). After adjusting for efﬁcacy-related withdrawals, the eval-
uated drug classes were associated with similar pain reductions
(NSAIDs: -18.2 [SE 1.2]; less potent opioids: -19.6 [SE 1.4] potent
opioids: -19.9 [SE 1.1]) (Figure). The meta-regression analysis did not
reveal differential effectiveness by treatment regimen, but found that
treatment groups with a higher proportion of male subjects and worse
baseline pain experienced greater pain reductions across all regimens
evaluated.
Conclusions: NSAIDs and opioids offer similar pain reduction in per-
sons with OA. The attenuated analgesic effect of opioids may be
explained by more severe pain at study onset, prior exposure to a
greater number of failed regimens, and longer duration of symptoms.
Given the similar efﬁcacy proﬁles of the different medications, the
prescription of these analgesics to knee OA patients should be consid-
ered primarily from the view of their respective toxicity proﬁles and
patients’ prior medication histories.
